Headache After Vaccination: An Update on Recent Clinical Trials and Real-World Reporting.

Autor: Garces KN; Division of Headache, Department of Neurology, University of Miami, Miller School of Medicine, Miami, FL, USA., Cocores AN; Division of Headache, Department of Neurology, University of Miami, Miller School of Medicine, Miami, FL, USA., Goadsby PJ; NIHR King's Clinical Research Facility & Headache Group-Wolfson CARD, King's College London, London, UK.; Department of Neurology, University of California, Los Angeles, Los Angeles, CA, USA., Monteith TS; Division of Headache, Department of Neurology, University of Miami, Miller School of Medicine, Miami, FL, USA. Tmonteith@med.miami.edu.
Jazyk: angličtina
Zdroj: Current pain and headache reports [Curr Pain Headache Rep] 2022 Dec; Vol. 26 (12), pp. 895-918. Date of Electronic Publication: 2022 Nov 23.
DOI: 10.1007/s11916-022-01094-y
Abstrakt: Purpose of Review: The aim of this review is to characterize headache as a vaccine adverse event (VAE) in clinical trials.
Recent Findings: Of the recent phase III vaccine RCTs (non-COVID-19), 53 studies reported on headache (13 infectious agents). The median rate (interquartile range) of headache was 15.6% (IQR: 9.6-37.6%). Of these, 24.5% of the RCTs reported headache greater in the vaccine group compared to the placebo/control group. In the herpes zoster vaccination trials, headache was more common in all active groups: median rate 33.9% (IQR: 29.7-40.5%) as compared to placebo: median rate 17.7% (IQR: 15.4-23.8%). Influenza and HPV vaccination trials were the 2nd and 3rd most common to have headache as a VAE. Of the 6 widely distributed COVID-19 vaccinations, median rate of post-vaccination headache was 39% (IQR: 28-50%). Headache is a common VAE in vaccine trials. Standardized grading methods, predictors of persistence, and treatment regimens are warranted.
(© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: